

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 December 2022 (01.12.2022)



(10) International Publication Number
WO 2022/246557 A1

(51) International Patent Classification:

A61K 31/42 (2006.01) A61P 25/00 (2006.01)
A61K 41/00 (2020.01) A61P 25/24 (2006.01)
A61N 2/00 (2006.01) C07D 261/04 (2006.01)

(21) International Application Number:

PCT/CA2022/050839

(22) International Filing Date:

26 May 2022 (26.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/193,643 27 May 2021 (27.05.2021) US

(71) Applicant: **MCGRX CORP.** [CA/CA]; 120-4838 Richard
RD SW, Calgary AB, T3E 6L1 (CA).

(72) Inventor: **MCGIRR, Alexander Robert Angus**; 4824 21
Ave. NW, Calgary, Alberta T3B 0W9 (CA).

(74) Agent: **MBM INTELLECTUAL PROPERTY LAW
LLP**; 275 Slater Street, 14th Floor, Ottawa, Ontario K1P
5H9 (CA).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: **ADJUNCTIVE D-CYCLOSERINE AUGMENTATION OF TRANSCRANIAL MAGNETIC STIMULATION (TMS)
THERAPY FOR MAJOR DEPRESSIVE DISORDER**




FIG. 12

(57) Abstract: There is provided adjunctive D-cycloserine (DCS) augmentation of transcranial magnetic stimulation (TMS) therapy for Major Depressive Disorder (MDD). There is also provided combination therapies and therapeutic methods that include intermittent or continuous theta-burst stimulation (iTBS or cTBS), high- or low-frequency stimulation or combinations thereof with D-cycloserine (DCS) to treat MDD in a patient and/or to improve and/or alleviate and/or reduce frequency of one or more symptoms of MDD as well as complications of MDD, including anxiety, cognitive function, and suicide.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*